Engineering T cells for adoptive therapy: outsmarting the tumor
Adoptive transfer of T cells gene-engineered with antigen-specific receptors, whether it be chimeric antigen receptors (CARs) or T cell receptors (TCRs), has proven its feasibility and therapeutic potential in the treatment of tumors. Despite clinical successes, the majority of patients experiences no or non-sustainable clearance of solid tumors, which is attributed to local T cell evasive mechanisms. A rapidly expanding understanding of molecular and cellular events that contribute to a reduction in numbers and/or activation of intra-tumor T cells has facilitated the development of gene-engineering strategies, enabling T cells to counter immune tolerance. Here, we present an overview of gene-engineering approaches and considerations to improve tumor-selectivity and effectiveness of adoptively transferred T cells.
|Persistent URL||dx.doi.org/10.1016/j.coi.2018.03.014, hdl.handle.net/1765/112853|
|Journal||Current Opinion in Immunology|
Kunert, A, & Debets, J.E.M.A. (2018). Engineering T cells for adoptive therapy: outsmarting the tumor. Current Opinion in Immunology (Vol. 51, pp. 133–139). doi:10.1016/j.coi.2018.03.014